According to SkyQuest, the global Cancer Gene Therapy Market size was valued at USD 2.38 billion in 2022 and is poised to grow from USD 2.86 billion in 2023 to USD 12.63 billion by 2031, growing at a CAGR of 20.42% in the forecast period (2024-2031).
Cancer has plagued the world and is probably the leading chronic disease affecting millions of people. Demand for novel cancer treatments and therapeutics is always high, which is projected to help boost the adoption of cancer gene therapy. Advancements in genetic engineering and the growing acceptance of gene therapies for multiple indications are forecasted to create new opportunities for cancer gene therapy providers in the future. The global cancer gene therapy market is segmented into therapy, indication, end user, and region.
Cancer Gene Therapy Market Overview:
| Report Coverage | Details |
| Market Revenue in 2023 | $ 2.86 Billion |
| Estimated Value by 2031 | $ 12.63 Billion |
| Growth Rate | Poised to grow at a CAGR of 20.42% |
| Forecast Period | 2024–2031 |
| Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Therapy, Indication, End User, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, Middle East & Africa, Latin America |
| Report Highlights | Growing acceptance of novel gene therapies for cancer treatment |
| Key Market Opportunities | Rising investments in gene and cancer research |
| Key Market Drivers | Growing number of cancer cases and high demand for novel treatments |
Segments covered in Cancer Gene Therapy Market are as follows:
- Therapy
Gene Induced Immunotherapy, Oncolytic Virotherapy, and Gene Transfer - Indication
Breast Cancer, Ovarian Cancer, Liver Cancer, Pancreatic Cancer, Lung Cancer, Prostate Cancer, and Others - End User
Hospitals, Diagnostic centers, Research Institutes, and Others
Gene Therapies for Breast Cancer Treatment are Slated to be Highly Popular Going Forward
The incidence of breast cancer around the world has risen substantially in recent years owing to growing awareness and increasing availability of advanced diagnostic procedures. High investments in R&D to develop new diagnostic and treatment procedures for breast cancer around the world are projected to help this segment lead the cancer gene therapy market. Gene transfer and suppression are mostly used to treat breast cancer via gene therapies.
Meanwhile, the demand for gene therapy to treat lung cancer is projected to shine bright across the forecast period. Lung cancer amounts to the biggest mortality rate of any other cancer indications, and this is why the demand for novel treatments to treat it is increasing at a rapid pace. Bad air quality due to increased air pollution levels has led to the high incidence of lung cancer, which is why this segment presents highly lucrative opportunities for cancer gene therapy providers.
Gene Induced Immunotherapy Remains Preferred Owing to High Emphasis on Fighting Cancer through the Immune System
Fighting cancer through the immune system has been the best approach proven to treat multiple types of cancers. Gene induced immunotherapy combines the advantages of immunotherapy and gene therapy to provide a much better treatment for cancer indications as compared to either one being used on its own. High investments in research and development of new therapies based on the immune response approach will also help this segment offer new opportunities for cancer gene therapy companies.
Most Cancer Gene Therapies are Slated to be Performed in Hospitals
Hospitals are projected to emerge as major end users of cancer gene therapies. Growing rates of hospitalization due to cancer and the high availability of novel gene therapies in the same are also estimated to help this segment hold a prominent chunk of market share. Biopharmaceutical companies are also estimated to be highly lucrative for cancer gene therapy providers as they focus on developing new cancer treatments and therapeutics.
Surging incidence of multiple types of cancers around the world makes this an opportune market. New as well as established cancer gene therapy providers should invest heavily in R&D to maximize their business scope.
https://www.prnewswire.com/news-releases/cancer-gene-therapy-market-to-attain-a-usd-12-63-billion-by-2031-advancements-in-gene-technologies-augment-development–skyquest-technology-302201473.html
Check out our AAV CDMO service to expedite your gene therapy research
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Skyline Therapeutics Receives FDA Orphan Drug Designation for Gene Therapy for Retinitis Pigmentosa
BOSTON & SHANGHAI, September 2, 2024 – Skyline Therapeutics, a gene therapy company focused on innovative treatments for rare and severe diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for SKG1108....
Novavax Receives Emergency Use Authorization for Updated Covid-19 Vaccine
Novavax has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its updated Covid-19 vaccine, NVX-CoV2705, joining other vaccine manufacturers in addressing evolving virus variants. The EUA permits the use of Novavax's...
Turn Biotechnologies Reports Historic Skin Cell Rejuvenation Breakthroughs at ESDR this Week
Company will present data from its successful rejuvenation of fibroblasts and keratinocytes to influential gathering of international dermatologists MOUNTAIN VIEW, Calif., Sept. 4, 2024 /PRNewswire/ -- Turn Biotechnologies, a developer of novel mRNA medicines and...
H5 influenza vaccines: What needs to be done to reduce the risk of a pandemic
As the global threat of H5N1 influenza looms with outbreaks across species and continents including the U.S., three international vaccine and public health experts say it is time to fully resource and support a robust strategy to address this and future potential...
Related Services
Plasmids GMP Services
AAV GMP Services
